548 views4 min read
PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation
Strengthens position to become a leader in the intradermal delivery of FDA prescription-based ketamine productsSupports commercializing novel uses and delivery methods of psychedelics TORONTO, July 21, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company... Read More...
